Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (SIGY) is a development-stage medical technology company whose news flow centers on its dialysis-like blood purification therapies and related corporate developments. Company announcements highlight progress on Sigyn Therapy, a novel blood purification technology aimed at pathogen-associated inflammatory disorders, as well as its oncology-focused platforms ImmunePrep, ChemoPrep, and ChemoPure.
News releases frequently cover clinical and regulatory milestones, such as plans for first-in-human feasibility studies of Sigyn Therapy in end-stage renal disease patients with endotoxemia and concurrent inflammation, drafting of an Investigational Device Exemption for submission to the U.S. Food and Drug Administration, and discussions of potential Breakthrough Device submissions. Investors can also find updates on annual and quarterly financial results, including the filing of Form 10-K and other SEC reports referenced in company communications.
Sigyn Therapeutics also issues news about capital markets and corporate actions, including its 1-for-40 reverse stock split and efforts to meet listing requirements for The Nasdaq Capital Market. Coverage includes participation in emerging growth and small-cap conferences, such as the Emerging Growth Conference and LD Micro Main Event, where management presents updates on the companys therapeutic pipeline and development plans.
In addition, third-party research coverage, such as reports from Goldman Small Cap Research, is sometimes summarized in press releases that describe Sigyn Therapeutics as a developer of next-generation blood purification therapies for life-threatening conditions without FDA-approved treatments. For investors and observers, the SIGY news feed offers a consolidated view of clinical planning, technology development, financing steps, and investor outreach activities related to the companys blood purification and oncology-support platforms.
Sigyn Therapeutics (OTCQB: SIGY) will present at LD Micro Main Event XIX on Tuesday, October 21, 2025 at 4:00 PM PT at the Hotel del Coronado in San Diego.
Jim Joyce, CEO and inventor, will deliver the company presentation. The three-day conference runs October 19–21, 2025, features about 120 companies presenting in half-hour slots, and includes one-on-one investor meetings and a closing reception.
Investors can attend in person or register to watch the virtual presentation.
Sigyn Therapeutics (OTCQB: SIGY) will present at LD Micro Main Event XIX on Tuesday, October 21, 2025 at 4:00 PM PT at the Hotel del Coronado in San Diego. CEO and inventor Jim Joyce will deliver the presentation and the company will be available for investor meetings during the three-day event running October 19–21, 2025.
The conference features ~120 companies presenting in half-hour slots and includes keynotes, company presentations, one-on-one investor meetings, and a closing reception. A virtual registration option is available for the presentation.
Sigyn Therapeutics (OTCQB:SIGY) has been featured in a new research report by Goldman Small Cap Research, highlighting the company's development of next-generation blood purification therapies. The company's flagship product, Sigyn Therapy™, is a first-in-class device targeting severe inflammatory disorders, primarily sepsis and end stage renal disease (ESRD).
The device has demonstrated capability to reduce bacterial toxins, inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. Additionally, Sigyn is developing medical devices to enhance cancer drug treatment effectiveness.
According to the research report, Sigyn plans to submit multiple Breakthrough Device submissions this year and expects to commence an ESRD feasibility study within the next 12 months. The study could yield data within 6 months of completion. Goldman Small Cap Research has issued a price target for SIGY, suggesting the company is currently undervalued compared to peers.
Sigyn Therapeutics (OTCQB:SIGY), a developer of next-generation blood purification therapies, is the subject of a new research report by Goldman Small Cap Research. The company's flagship product, Sigyn Therapy™, is a first-in-class device targeting severe inflammatory disorders, primarily sepsis and end-stage renal disease (ESRD).
The device has demonstrated effectiveness in reducing bacterial toxins, inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. Additionally, Sigyn is developing medical devices to enhance cancer drug treatment effectiveness.
According to the research report, Sigyn plans to submit multiple Breakthrough Device submissions this year and expects to commence an ESRD feasibility study within the next 12 months. Data from this trial could be available within 6 months of study completion.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Sigyn Therapeutics (SIGY)?
What is the market cap of Sigyn Therapeutics (SIGY)?
